Bristol Myers Squibb-Backed Cancer Drug Cuts Progression Risk 60% in Phase 3 Lung Cancer Trial

07:08 AM EDT, 10/26/2026 (MT Newswires) -- Bristol-Myers Squibb Company (BMY) said Monday that SystImmune's parent company, Sichuan Biokin Pharmaceutical, reported that the investigational drug izalontamab brengitecan reduced the risk of disease progression or death by 60% versus chemotherapy in a Phase 3 trial of previously treated EGFR-mutated non-small cell lung cancer. Median progression-free survival reached 11.1 months, compared with 5.7 months for chemotherapy, while response rates were 60.2% versus 34.5%, it said. The company added that the overall survival data remain immature. It said Grade 3 or higher treatment-related adverse events were predominantly hematologic.